Zobrazeno 1 - 3
of 3
pro vyhledávání: '"E E, Dumbrava"'
Autor:
H, Park, G I, Shapiro, X, Gao, A, Mahipal, J, Starr, M, Furqan, P, Singh, A, Ahrorov, L, Gandhi, A, Ghosh, D, Hickman, P D, Gallacher, A, Wennborg, E C, Attar, M M, Awad, S, Das, E E, Dumbrava
Publikováno v:
ESMO Open. 7:100573
We conducted a phase I, multicenter, open-label, dose-finding, and expansion study to determine the safety and preliminary efficacy of eprenetapopt (APR-246) combined with pembrolizumab in patients with advanced/metastatic solid tumors (ClinicalTrial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e793d4bbecadb6c6c65be85d9409b22b
https://doi.org/10.1016/j.esmoop.2022.100573
https://doi.org/10.1016/j.esmoop.2022.100573
Autor:
Gouda MA; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston., Shunyakova J; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston., Naing A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston., Dumbrava E; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston., Hong DS; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston., Yuan Y; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston., Yang P; Department of Palliative, Rehabilitation, and Integrative Medicine, The University of Texas MD Anderson Cancer Center, Houston., Myers A; Department of Diagnostic and Biomedical Sciences, School of Dentistry, The University of Texas Health Science Center at Houston, Houston, USA., Liang Y; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston., Peng J; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston., Karp D; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston., Tsimberidou AM; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston., Rodon J; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston., Yap TA; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston., Piha-Paul SA; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston., Meric-Bernstam F; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston., Fu S; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston. Electronic address: siqingfu@mdanderson.org.
Publikováno v:
ESMO open [ESMO Open] 2024 Jun; Vol. 9 (6), pp. 103486. Date of Electronic Publication: 2024 Jun 08.
Publikováno v:
Medicina interna [Med Interna (Bucur)] 1956 Dec; Vol. 8 (8), pp. 1162-7.